Interval between hepatocellular carcinoma treatment and interferon‑free direct‑acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence

  • Authors:
    • Hiroya Iida
    • Rie Osaki
    • Takehide Fujimoto
    • Hiromitsu Maehira
    • Haruki Mori
    • Naomi Kitamura
    • Akira Andoh
    • Masaji Tani
  • View Affiliations

  • Published online on: April 24, 2019     https://doi.org/10.3892/mco.2019.1847
  • Pages: 99-105
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Interferon (IFN) has been identified to suppress carcinogenesis when used for treating hepatitis C virus (HCV) infections. Treatment with IFN‑free direct‑acting antiviral agents (DAAs) is an acceptable alternative, even in elderly patients or patients who have been treated for hepatocellular carcinoma (HCC), because it has a lower incidence of side effects and higher sustained virological response (SVR) rate compared with IFN treatment. However, the suppression of carcinogenesis by DAAs is unclear. In the present study, 19 patients who underwent DAA treatment following treatment for HCC between January 2015 and March 2017 were retrospectively investigated. The clinical data were compared between 9 patients with HCC recurrence following DAA treatment (recurrence group) and 10 patients without HCC recurrence (no‑recurrence group). The 1‑year cumulative recurrence rate of HCC following SVR was as high as 50.2%. Age and sex did not significantly differ between the two groups, and the average number of HCC treatments prior to DAA treatment was also not significantly different between the recurrence and no‑recurrence groups (3.2 and 2.2, respectively). The median interval between the final HCC treatment and the commencement of DAA treatment was 88 days in the recurrence group, which was significantly less compared with 790 days in the no‑recurrence group (P=0.018). An interval of 120 days or more from final HCC treatment to the commencement of DAA treatment was a significant independent factor of no HCC recurrence following DAA treatment (P=0.028). A high HCC recurrence rate was identified following DAA treatment in patients with a history of HCC treatment. Therefore, there should be at least a 4‑month interval from the final HCC treatment to the commencement of DAA treatment to ensure no HCC recurrence.

References

1 

Asselah T and Marcellin P: New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 31 (Suppl 1):S68–S77. 2011. View Article : Google Scholar

2 

Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M and Chevret S: Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death. Gut. 47:131–136. 2000. View Article : Google Scholar : PubMed/NCBI

3 

Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, et al: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka hepatocellular carcinoma prevention study group. Ann Intern Med. 129:94–99. 1998. View Article : Google Scholar : PubMed/NCBI

4 

Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A and Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 24:141–147. 1996. View Article : Google Scholar : PubMed/NCBI

5 

Hiramatsu N, Oze T and Takehara T: Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 45:152–161. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Cammà C, Giunta M, Andreone P and Craxì A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol. 34:593–602. 2001. View Article : Google Scholar : PubMed/NCBI

7 

Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N and Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 32:228–232. 2000. View Article : Google Scholar : PubMed/NCBI

8 

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 134:963–967. 2001. View Article : Google Scholar : PubMed/NCBI

9 

Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, et al: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 44:1543–1554. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, et al: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 52:833–844. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J and Mole LA: A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 9:509–516.e1. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, et al: Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 136:138–148. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 59:2083–2091. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, et al: Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial. J Viral Hepat. 21:762–768. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, et al: Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial. Lancet Infect Dis. 15:645–653. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, et al: Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 62:1037–1046. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, et al: Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 65:719–726. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, et al: Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 65:727–733. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B, et al: Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J Hepatol. 66:1138–1148. 2017. View Article : Google Scholar : PubMed/NCBI

20 

ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr: Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts, . J Hepatol. 65:734–740. 2016.PubMed/NCBI

21 

Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ and Kulik L: Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 66:1173–1181. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Manthravadi S, Paleti S and Pandya P: Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: A systematic review and meta-analysis. Int J Cancer. 140:1042–1049. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Beste LA, Green PK, Berry K, Kogut MJ, Allison SK and Ioannou GN: Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 67:32–39. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Iida H, Kaibori M, Matsui K, Ishizaki M and Kon M: Assessing the feasibility of clinicopathological features of hepatic resection for hepatocellular carcinoma in patients over 80 years of age. Mol Clin Oncol. 6:29–38. 2017. View Article : Google Scholar : PubMed/NCBI

25 

Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Suzuki Y, Saitoh S, Arase Y, et al: Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 89:476–483. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Alberti A and Piovesan S: Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction? Liver Int. 37:802–808. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, et al: The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One. 12:e01827102017. View Article : Google Scholar : PubMed/NCBI

28 

Nault JC and Colombo M: Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 65:663–665. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, Vendemiale G and Serviddio G: DAAs rapidly reduce inflammation but increase serum VEGF level: A rationale for tumor risk during Anti-HCV treatment. PLoS One. 11:e01679342016. View Article : Google Scholar : PubMed/NCBI

30 

Tsai PC, Huang CF and Yu ML: Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy. J Hepatol. 66:4642017. View Article : Google Scholar : PubMed/NCBI

31 

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL and Ho SB: Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol. 11:1503–1510. 2013. View Article : Google Scholar : PubMed/NCBI

32 

Cortesi PA, Mantovani LG, Ciaccio A, Rota M, Mazzarelli C, Cesana G, Strazzabosco M and Belli LS: Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis. Am J Transplant. 15:1817–1826. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V III, Simon T, Abou-Samra AB, Chung RT and Butt AA: The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 67:2244–2253. 2018. View Article : Google Scholar : PubMed/NCBI

34 

Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q and Morisco F; Special Interest Group on Hepatocellular carcinoma and new anti-HCV therapies' of the Italian Association for the Study of the Liver, : Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Dig Liver Dis. 50:1105–1114. 2018. View Article : Google Scholar : PubMed/NCBI

35 

Singh S, Nautiyal A and Loke YK: Oral direct-Acting antivirals and the incidence or recurrence of hepatocellular carcinoma: A systematic review and meta-analysis. Frontline Gastroenterol. 9:262–270. 2018. View Article : Google Scholar : PubMed/NCBI

36 

Tampaki M, Savvanis S and Koskinas J: Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: Evidence and pathophysiological issues. Ann Gastroenterol. 31:670–679. 2018.PubMed/NCBI

37 

Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND and Singal AG: Systematic review with meta-analysis: Recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 48:127–137. 2018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2019
Volume 11 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Iida, H., Osaki, R., Fujimoto, T., Maehira, H., Mori, H., Kitamura, N. ... Tani, M. (2019). Interval between hepatocellular carcinoma treatment and interferon‑free direct‑acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence. Molecular and Clinical Oncology, 11, 99-105. https://doi.org/10.3892/mco.2019.1847
MLA
Iida, H., Osaki, R., Fujimoto, T., Maehira, H., Mori, H., Kitamura, N., Andoh, A., Tani, M."Interval between hepatocellular carcinoma treatment and interferon‑free direct‑acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence". Molecular and Clinical Oncology 11.1 (2019): 99-105.
Chicago
Iida, H., Osaki, R., Fujimoto, T., Maehira, H., Mori, H., Kitamura, N., Andoh, A., Tani, M."Interval between hepatocellular carcinoma treatment and interferon‑free direct‑acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence". Molecular and Clinical Oncology 11, no. 1 (2019): 99-105. https://doi.org/10.3892/mco.2019.1847